B4GALT5: A Potential Drug Target and Biomarker (G9334)

Target Name: B4GALT5

NCBI ID: G9334

B4GALT5

B4GALT5: A Potential Drug Target and Biomarker

Beta4-GalT IV, also known as B4GALT5, is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the G protein-coupled receptor (GPCR) family and is involved in the regulation of a wide range of physiological processes in the body. Despite its importance, B4GALT5 is still not well understood, and there is limited research on its potential drug targets or biomarkers. In this article, we will explore the potential of B4GALT5 as a drug target and biomarker.

The B4GALT5 Protein

B4GALT5 is a 21-kDa protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the GPCR family and is involved in the regulation of a wide range of physiological processes in the body. The B4GALT5 protein is composed of 21 amino acid residues and has a calculated pI of 11.92. It is expressed in the brain, heart, and kidneys and is also found in various other tissues, including the placenta, spleen, and pancreas.

B4GALT5 is involved in the regulation of a wide range of physiological processes, including blood pressure, heart rate, and inflammation. It is a GPCR that is involved in the regulation of angiotensin II signaling, a hormone that plays a critical role in the regulation of blood pressure and cardiovascular health.

B4GALT5 is also involved in the regulation of pain perception and neuroinflammation. It is a potent inhibitor of the pain-sensitive GABAergic neurotransmitter, GABA, and has been shown to have anti-inflammatory effects.

B4GALT5 Interactions

B4GALT5 is a protein that is involved in multiple interactions with other proteins. One of the most significant interactions of B4GALT5 is with the protein PyR, which is a GABA receptor modulator. PyR is a GABAergic neurotransmitter and is involved in the regulation of anxiety, depression, and other mood-related disorders. B4GALT5 has been shown to interact with PyR and to modulate the activity of PyR.

Another interaction of B4GALT5 is with the protein TRPV4, which is a voltage-gated ion channel that is involved in pain perception. B4GALT5 has been shown to interact with TRPV4 and to modulate its activity.

B4GALT5 as a Drug Target

B4GALT5 is a protein that is involved in multiple physiological processes and has been shown to have a variety of potential drug targets. One of the most promising potential drug targets for B4GALT5 is the GABAergic neurotransmitter system. GABA is an inhibitory neurotransmitter that has been shown to have a variety of therapeutic effects, including the regulation of anxiety, depression, and other mood-related disorders.

B4GALT5 has been shown to interact with PyR, which is a GABAergic neurotransmitter and is involved in the regulation of anxiety, depression, and other mood-related disorders. It is possible that B4GALT5 may play a role in the regulation of GABAergic neurotransmitter systems and may be a potential drug target for mood-related disorders.

Another potential drug target for B4GALT5 is the TRPV4,

Protein Name: Beta-1,4-galactosyltransferase 5

Functions: Catalyzes the synthesis of lactosylceramide (LacCer) via the transfer of galactose from UDP-galactose to glucosylceramide (GlcCer) (PubMed:24498430). LacCer is the starting point in the biosynthesis of all gangliosides (membrane-bound glycosphingolipids) which play pivotal roles in the CNS including neuronal maturation and axonal and myelin formation (By similarity). Plays a role in the glycosylation of BMPR1A and regulation of its protein stability (By similarity). Essential for extraembryonic development during early embryogenesis (By similarity)

The "B4GALT5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B4GALT5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets